doi:10.1016/j.pep.2007.06.003
Copyright © 2007 Elsevier Inc. All rights reserved.
Profiling of membrane protein variants in a baculovirus system by coupling cell-surface detection with small-scale parallel expression
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Michael A. Hansona, Alexei Broounb, 1, Kent A. Bakerb, Veli-Pekka Jaakolaa, Chris Rotha, Ellen Y.T. Chiena, Alexander Alexandrova, Jeffrey Velasqueza, Leila Davisb, Mark Griffitha, Kin Moya, Barbie K. Ganser-Pornillosb, Yuanzi Huab, Peter Kuhnb, Sam Ellisc, Mark Yeagera, b, d and Raymond C. Stevensa,
, 
aDepartment of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR101, La Jolla, CA 92037, USA
bDepartment of Cell Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
cThomson Instrument Company, 1121 South Cleveland Street, Oceanside, CA 92054, USA
dDivision of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037, USA
Received 26 April 2007;
revised 12 June 2007.
Available online 27 June 2007.
Abstract
Production of structure-grade mammalian membrane proteins in substantial quantities has been hindered by a lack of methods for effectively profiling multiple constructs expression in higher eukaryotic systems such as insect or mammalian cells. To address this problem, a specialized small-scale eukaryotic expression platform by Thomson Instrument Company (Vertiga-IM) was developed and used in tandem with a Guava EasyCyte microcapillary 96-well cytometer to monitor cell density and health and evaluate membrane protein expression. Two proof of concept experiments were conducted using the human β2-adrenergic receptor (β2AR) and the gap junction protein connexin26 (Cx26) in a baculovirus expression system. First, cell surface expression was used to assess the expression levels of 14 β2AR truncation variants expressed using the Vertiga-IM shaker. Three of these variants were then compared to wild-type β2AR using three metrics: cell surface expression, saturation ligand binding and protein immunoblot analysis of dodecylmaltoside extracted material. Second, a series of systematic Cx26 truncation variants were evaluated for expression by protein immunoblot analysis. The cumulative results for these two systems show that the Vertiga-IM instrument can be used effectively in the parallel insect cell microexpression of membrane protein variants, and that the expression of cell surface molecules as monitored with the Guava EasyCyte instrument can be used to rapidly assess the production of properly folded proteins in the baculovirus expression system. This approach expedites the in vitro evaluation of a large number of mammalian membrane protein variants.
Keywords: Membrane protein expression; Vertiga-IM; Microcapillary 96-well cytometer
Fig. 1. Membrane topology of receptor truncations and variants. (a) Membrane topology of the β2AR protein sequence with numbers and pins indicating the location of truncations for the 14 constructs used in this experimental series. Numbers and pins in red indicate the mutations focused on for further study as highlighted in Fig. 3 and Fig. 4. (b) Membrane topology of a Cx26 subunit. The four transmembrane domains (M1–M4) are denoted with gray boxes. Areas that were mutated are the N-terminus (red), extracellular loop 1 (yellow), the intracellular M2–M3 loop (green), extracellular loop 2 (blue) and the C-terminus (magenta).
 |
Fig. 2. Example of β2AR cell surface expression. (a) Histogram of cell count (events) vs. mean fluorescence intensity (MFI). For cases in which the expressing cells are not clearly delineated close to the limit of detection of 10 MFI, the final reported MFI is derived from the mean fluorescence of the highest 70% of the total cell population (top panel, expressing cell population framed by solid line). For cases in which a clearly expressing population of cells is detectable (bottom panel, expressing cell population framed by solid line), the reported MFI is derived from all cells in the expressing population, which is frequently much greater than 70%. (b) Cell surface expression of β2AR arranged from the longest construct (1–408) to the shortest (1–343). Both MFI and %CV are calculated from two protocols described in (a). The latter protocol was preferred and utilized when possible. In general, as the MFI decreases the %CV increases indicating a progressive loss of a clearly expressing cell population.
Fig. 3. Saturation ligand binding data for β2AR. (a) [3H]DHA isothermal binding curves to a selected set of C-terminal β2AR truncation variants compared to wild-type. The data represent five repetitions of three assay replicates. (b) Protein immunoblot of isolated Sf9 cell membranes.
Fig. 4. Expression comparison of β2AR truncations relative to wild-type. Relative expression levels of three selected truncation variants of β2AR relative to wild-type as represented by the maximal receptor expression levels (Bmax) of the crude membrane fraction (striped), cell surface fluorescence (gray) and by protein immunoblot analysis (dotted).
Fig. 5. Cx26 parallel expression in Sf9 cells using the Vertiga-IM. Estimated relative expression levels of expressed variants on a relative scale of 1–10, as determined by protein immunoblot analysis. The associated regions of the protein as described in Fig. 1b are indicated. Full definition of the constructs are described in Supplementary Fig. 1.
Table 1.
Bmax and Kd for β2AR wild-type and truncations

Table 2.
Correlation table for relative expression levels


Corresponding author. Fax: +1 858 784 9483.
1 Present address: Pfizer, Inc., 10770 Science Center Drive, CB2/2213, San Diego, CA 92121, USA.